title: Effect of high-flux hemodialysis on delayed hepatitis B virus vaccination response in hemodialysis patients.
abstract: OBJECTIVE
  The aim of the study was to evaluate the effect of high-flux (HF) hemodialysis (HD) on delayed protective hepatitis B virus (HBV) antibody seroconversion in HD patients who had no response to the classic third dose of HBV vaccination.
  
  
  METHODS
  We performed a prospective cohort study. Forty-two patients who did not respond within 6 months after the third dose of the vaccination were enrolled in the study. The patients were randomized to either an HF HD treatment group (n =19) or a conventional HD treatment group (n = 23). Patients' serum hepatitis B surface antibody levels were followed monthly.
  
  
  RESULTS
  After 6 months of follow-up, there were 15 (78.9%) patients in HF group and 7 (30.4%) patients in the control group showing delayed HBV vaccination response. The level of antibody titer of HBV vaccination responders was 103.6 ± 48.3 mIU/mL in the HF group and 23.5 ± 15.7 mIU/mL in the control group. The antibody titer did not correlate with sex, age, serum albumin, or hemoglobin in either group. Four patients in control group lost HBV vaccination response > 2 times after 3 months of follow-up, whereas no patients in the HF group lost HBV vaccination response.
  
  
  CONCLUSIONS
  Hemodialysis patients who do not respond to the classic third dose of HBV vaccination could reobtain a delayed higher protective HBV antibody seroconversion rate by HF HD without other intervention.
authors.affiliation: Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: He
authors.forename: Fuquan
authors.initials: F
authors.lastname: Wu
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.forename: Jianghua
authors.initials: J
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis / Q000379:methods*; D013997:Time Factors
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines